Katherine Cross
Family · Oak Ridge, TNNPI 1225493091
Payments from drug & device makers
Across 252 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$786
- Sanofi$460
- Boehringer Ingelheim$322
- Regeneron Healthcare Solutions, Inc.$319
- Grifols USA, LLC$302
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,26098%
- Education$1312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $1,039 |
| GSK | 53 | $786 |
| Sanofi | 22 | $460 |
| Boehringer Ingelheim | 10 | $322 |
| Regeneron Healthcare Solutions, Inc. | 13 | $319 |
| Grifols USA, LLC | 12 | $302 |
| Insmed, Inc. | 14 | $286 |
| Verona Pharma, Inc. | 17 | $272 |
| Actelion Pharmaceuticals US, Inc. | 9 | $248 |
| Amgen | 11 | $216 |
| Electromed, Inc. | 9 | $178 |
| Viatris Specialty LLC | 14 | $173 |
| Merck | 5 | $151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $135 |
| Sanofi-aventis U.S. LLC | 1 | $98 |
| Mylan Specialty L.p. | 4 | $95 |
| Inspire Medical Systems, Inc. | 2 | $77 |
| La Jolla Pharmaceutical Company | 3 | $72 |
| Baxter Healthcare | 2 | $72 |
| Mallinckrodt Hospital Products Inc. | 2 | $56 |
| Liquidia Technologies, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,391 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 563 | $493,586 |
| Breo ElliptaFluticasone/Vilanterol | 298 | $173,510 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $108,133 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 103 | $100,557 |
| Spiriva RespimatTiotropium Bromide | 72 | $61,227 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 62 | $47,534 |
| SymbicortBudesonide/Formoterol Fumarate | 125 | $45,296 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 53 | $35,251 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 50 | $31,014 |
| Spiriva HandihalerTiotropium Bromide | 40 | $27,142 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 388 | $18,463 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 66 | $17,498 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $15,247 |
| Arnuity ElliptaFluticasone Furoate | 30 | $11,544 |
| Wixela InhubFluticasone Propion/Salmeterol | 54 | $8,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $786 | $741,421987 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,039 | $145,852228 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $322 | $127,493175 claims |
| Grifols USA, LLCProlastin C | $302 | $108,13311 claims |
| MerckDulera, Asmanex | $151 | $10,70731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Oak Ridge
- Brittany AdamsOak Ridge$19K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.